Get the Stockscreener App
412.56
0.92%
3.77
After Hours:
413.00
0.44
+0.11%
Natera Inc stock is traded at $412.56, with a volume of 1.60M.
It is up +0.92% in the last 24 hours and up +22.53% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$408.79
Open:
$410
24h Volume:
1.60M
Relative Volume:
1.13
Market Cap:
$59.47B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-251.38
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
+11.69%
1M Performance:
+22.53%
6M Performance:
+109.03%
1Y Performance:
+152.08%
1-Day Range:
$407.48
$415.75
1-Week Range:
$363.96
$415.75
52-Week Range:
$157.43
$415.75
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
412.56 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
675.00 | 249.58B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
224.49 | 157.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
172.79 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
270.37 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Australia
Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com
Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan
Final Trades: Hewlett Packard, Natera and UnitedHealth - CNBC
Natera options flow shows 12.6:1 put/call ratio near 52-week high - Investing.com
NTRA Maintained by RBC Capital -- Price Target Raised to $460 - GuruFocus
RBC Capital raises Natera stock price target on MRD testing growth - Investing.com
Natera Is Maintained at Outperform by RBC Capital - moomoo.com
RBC Capital maintains Outperform rating on Natera, $460 price target - TradingView
Natera’s Critical Pivot to Oncology - Nanalyze
RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating - marketscreener.com
Natera, Inc. (NTRA) Stock Price, News, Quote & History - ca.finance.yahoo.com
Natera Inc (NTRA) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 73/100 - gurufocus.com
Svetlana Nikic Celebrates Natera’s Signatera Milestone in Japan - Oncodaily
Natera, Inc. (NTRA) stock price, news, quote and history - Yahoo Finance Australia
Natera stock gains 2.75 percent after Japan test approval - AD HOC NEWS
Has Natera (NTRA) Run Ahead Of Fair Value After Its Japan Signatera Approval? - simplywall.st
Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media
Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar - Yahoo Finance
Signatera Surges in Liquid Biopsy Race with New Lung Cancer Data and a Japan Approval - insideprecisionmedicine.com
Form 144 Natera For: 23 September By Investing.com - Investing.com Canada
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Yahoo Finance
$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan
Natera, Inc.Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer - marketscreener.com
Why Is Natera (NTRA) Stock Soaring Today - Yahoo Finance
A Look at Natera Inc (NTRA) After 5.5% Gain -- GF Value $219.69 vs Price $390.90 - GuruFocus
Behavioral Patterns of NTRA and Institutional Flows - Stock Traders Daily
Natera Inc stock reaches all-time high at 373.58 USD By Investing.com - Investing.com Nigeria
Natera Inc Stock (NTRA) Moved Up by 5.67% on Sep 22: Facts Behind the Movement - TradingKey
Natera gains as fresh Signatera lung cancer data and upbeat analyst sentiment support shares - Quiver Quantitative
NTRA Looks 68.7% Overvalued on GF Value™ - gurufocus.com
Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer - Finviz
Natera’s Signatera Receives Japanese Approval as CDx for Muscle-Invasive Bladder Cancer - GenomeWeb
Natera Inc stock reaches all-time high at 373.58 USD - Investing.com
Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027 - TradingView
Uber, Micron, Datadog And A Health Care Stock: CNBC’s ‘Final Trades’ - Benzinga
A cancer test receives its second Japan approval in three months to guide bladder-cancer treatment. - Stock Titan
Enterprise value to EBITDA ratio of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA.CI - TradingView
Final Trade: Uber, Micron, Natera and Datadog - CNBC
How Lung Cancer Data Will Impact Natera Stock Investors - simplywall.st
Natera, Inc. (NTRA) Stock Analysis: Amidst Rapid Growth, What Lies Ahead for This Diagnostics Leader? - DirectorsTalk Interviews
Natera stock gains as new lung cancer study supports Signatera value - AD HOC NEWS
Natera (NTRA) Study Of 1,100 Patients Supports Signatera In Lung Cancer - simplywall.st
Why Natera (NTRA) Is Up 12.3% After Landmark Lung Cancer MRD Data At IASLC 2026 - Yahoo Finance
Natera (NTRA) Stock Fair Value Rises After Signatera And Guidance Drive Analyst Revisions - Yahoo Finance
Natera CEO Steven Chapman Sells 1,698 Shares for $545,000 - The Motley Fool
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM - Business Wire
Show Me The Money: Natera Delivers Over 120% Gain In Just About A Year - RTTNews
Natera co-founder Sheena sells $3.2m in shares - Investing.com
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):